The complex relationship between upper urinary tract and bladder cancer: clinical and predictive issues
Editorial

The complex relationship between upper urinary tract and bladder cancer: clinical and predictive issues

Francesca Sanguedolce1, Luigi Cormio2

1Department of Pathology, University Hospital, Foggia, Italy; 2Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy

Correspondence to: Francesca Sanguedolce. Department of Pathology, University Hospital, Foggia, Viale Pinto 1, Foggia 71121, Italy. Email: fradolce@hotmail.com.

Provenance: This is a Guest Editorial commissioned by Section Editor Xiao Li (Department of Urology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China).

Comment on: Miyake M, Tatsumi Y, Matsumoto H, et al. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma. BJU Int 2018;121:764-73.


Submitted Apr 23, 2018. Accepted for publication May 07, 2018.

doi: 10.21037/tau.2018.05.07


Miyake et al. (1) analyzed the outcome of a series of Bacillus Calmette-Guérin (BCG)-treated non-muscle invasive bladder cancer (NMIBC) occurring after upper tract urothelial carcinoma (UTUC) in comparison to a “control” group of primary NMIBC. Their results, as well as the study concept itself, raise some intriguing issues on a quite controversial topic.


UTUC and urothelial bladder cancer (UBC): disparate and/or Siamese twins?

First of all, UTUC has traditionally been considered the twin tumor of UBC, since both stem from the same tissue, i.e., the transitional lining of the urinary tract (2). Such consideration, along with its very low frequency (almost 5–10% of all UC), have resulted in outlining treatment strategies for UTUC on the basis of UBC (3).

Recently, several attempts have been made to better understand the complex nature of UTUC, inducing some authors to define UTUC and UBC “disparate twins” due to the coexistence of both similarities (i.e., cell of origin, histology types, biological features) and discrepancies (diagnostic and prognostic role of gender, limitations in staging and treatment) between them (4). On a molecular basis, a prospective assessment of cell cycle and proliferative tissue markers disclosed close resemblance between UTUC and UBC (5). A recent comprehensive genomic characterization of UTUC (6) conversely revealed novel mutations and mutation frequencies in comparison to UBC, and identified four expression subtypes with unique molecular profiles and clinical correlates with features that were similar but did not overlap those of the established bladder subtypes (7).

While “disparate” on a pathological and biological basis, UTUC and UBC can be “Siamese” due to their close clinical connections. Upper tract recurrence (UTR) in UBC as well as intravesical recurrence (IVR) in UTUC may occur as well-known complications of the surgical management in both tumors. In this setting, UTR typically arises after a longer than 3 years’ disease-free survival (8), with urethral tract involvement at radical cystectomy (RC) being a significant predictor of UTR in both sexes. Although uncommon, such complication may be dismal due to its frequent detection at a symptomatic stage, despite the patients’ adherence to follow-up protocols (8).


UTUC and UBC: who is the cat and who is the tiger?

Another common feature shared by UTUC and UBC is difficulty in predicting disease outcome.

Most efforts have initially been driven towards factors predicting the outcome of UBC, particularly non-muscle invasive BC (NMIBC). The European Organization for Research and Treatment of Cancer (EORTC) risk tables and the Spanish Urological Club for Oncological Treatment (CUETO) scoring model remain a standpoint in this issue but research is strongly moving towards the identification of molecular markers that could better predict disease outcome (9,10).

Since UTUC is considered an aggressive disease with >60% of cases presenting with invasion at diagnosis, risk stratification is advisable in order to choose the proper surgical and/or medical treatment option (11). Similarly to NMIBC, clinical and pathological parameters (i.e., tumor multifocality, size, stage and grade, patient’s gender, and so on) continue to play a role even though studies addressing their role have yielded conflicting results and limited evidence overall (12,13). A large multicentric Canadian study described old age, tumor location in both the renal pelvis and the ureter, treatment with adjuvant systemic chemotherapy and extravesical ureterectomy or laparoscopic radical nephroureterectomy (RNU) as independent risk factors for IVR (14). As opposed to these findings, a meta-analysis of 40 studies including 12,010 patients failed to confirm such statistical association, rather suggesting that gender, location (renal pelvis vs. ureteral), stage, tumor size and concomitant BC are significantly correlated to subsequent IVR after RNU (15). In the last decade, several studies have been published addressing the role of different markers to predict IVR, such as cell inflammation-based parameters (12,16), the gross hematuria and the preoperative serum creatinine level (17), and diagnostic ureteroscopy (18). Their results have been biased by intrinsic limitations, namely the retrospective nature and relatively small number of cases in single center studies. Further attempts of risk stratification for IVR have been made, taking into account from time to time the above-mentioned parameters along with additional ones, such as papillary tumor architecture and lymphovascular invasion (19), and even the impact of different chemotherapy regimens (20). Current guidelines from the European Association of Urology (21) suggest a risk stratification based on three categories of predictors of increased risk for IVR namely, (I) patient-specific factors (i.e., male gender, previous BC, smoking and preoperative chronic kidney disease), (II) tumour-specific factors (i.e., positive preoperative urinary cytology, ureteral location, multifocality, invasive pT stage, and necrosis), and (III) treatment-specific factors (i.e., laparoscopic approach, extravesical bladder cuff removal, and positive surgical margins). However, so far there are no validated nomograms.

Strategies to prevent IVR after treatment for UTUC mostly focus on the use of postoperative prophylactic intravesical chemotherapy. In view of the intraluminal seeding hypothesis, it finds a rationale in the putative ability of the chemotherapic agent to prevent tumor cells implantation. Evidence has been provided that a significant decrease in IVR is achieved under such strategy (22), and intravesical chemotherapy seems to be even more effective in peculiar pathological and molecular settings (i.e., lack of EGFR, low-level Ki67, pre-operative positive cytology) (23).


Post-UTUC NMIBCs: are they really different and why?

IVR usually develop in up to 50% of patients during surgical follow-up after RNU (12) with cumulative incidence rates at 1 and 5 years after treatment as high as 31.0% and 48.4%, respectively, in one series (24), the most frequent site being around the excised bladder cuff. Furthermore, post-surgical IVR may be a significant predictor of later urethral recurrence (25). In order to find parameters able to predict the outcome of such IVRs, Tanaka et al. examined a series of 241 IVRs after RNU for UTUC; according to their analysis, multiplicity, pT1 stage, concomitant carcinoma in situ (CIS) and lack of BCG treatment were independent risk factors for subsequent IVR and/or progression (24). Miyake et al. (1) report that NMIBC occurring after RNU for UTUC carry a worse prognosis after intravesical BCG than their primary bladder counterpart, suggesting that such patients are inherently poor responders to BCG exposure, and this is a very novel finding providing a ground for further research in this field.


Acknowledgements

None.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. Miyake M, Tatsumi Y, Matsumoto H, et al. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma. BJU Int 2018;121:764-73. [Crossref] [PubMed]
  2. Mathieu R, Bensalah K, Lucca I, et al. Upper urinary tract disease: what we know today and unmet needs. Transl Androl Urol 2015;4:261-72. [PubMed]
  3. Szarvas T, Modos O, Horvath A, et al. Why are upper tract urothelial carcinoma two different diseases? Transl Androl Urol 2016;5:636-47. [Crossref] [PubMed]
  4. Green DA, Rink M, Xylinas E, et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 2013;189:1214-21. [Crossref] [PubMed]
  5. Krabbe LM, Lotan Y, Bagrodia A, et al. Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract – is there evidence for discordant biology. J Urol 2014;191:926-31. [Crossref] [PubMed]
  6. Moss TJ, Qi Y, Xi L, et al. Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur Urol 2017;72:641-9. [Crossref] [PubMed]
  7. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22. [Crossref] [PubMed]
  8. Sanderson KM, Cai J, Miranda G, et al. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1069 patients with 10-year follow-up. J Urol 2007;177:2088-94. [Crossref] [PubMed]
  9. Sanguedolce F, Bufo P, Carrieri G, et al. Predictive markers in bladder cancer: do we have molecular markers ready for clinical use? Crit Rev Clin Lab Sci 2014;51:291-304. [Crossref] [PubMed]
  10. Sanguedolce F, Cormio A, Bufo P, et al. Molecular markers in bladder cancer: Novel research frontiers. Crit Rev Clin Lab Sci 2015;52:242-55. [Crossref] [PubMed]
  11. Leow JJ, Chong KT, Chang SL, et al. Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open 2017;1:e000126. [Crossref] [PubMed]
  12. Cho YH, Se YH, Chung SJ, et al. Predictors of intravesical recurrence after radical nephrouretereterectomy for upper urinary tract urothelial carcinoma: an inflammation-based prognostic score. Korean J Urol 2014;55:453-9. [Crossref] [PubMed]
  13. Narukawa T, Hara T, Arai E, et al. Tumour multifocality and grade predict intravesical recurrence after nephroureterectomy in patients with upper urinary tract urothelial carcinoma without a history of bladder cancer. Jpn J Clin Oncol 2015;45:488-93. [Crossref] [PubMed]
  14. Fradet V, Mauermann J, Kassouf W, et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. Urol Oncol 2014;32:839-45. [Crossref] [PubMed]
  15. Yuan H, Chen X, Liu L, et al. Risk factors for intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis. Urol Oncol 2014;32:989-1002. [Crossref] [PubMed]
  16. Kishimoto N, Takao T, Kuribayashi S, et al. The neutrophil-to-lymphocyte ratio as a predictor of intravesical recurrence in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy. Int J Clin Oncol 2017;22:153-8. [Crossref] [PubMed]
  17. Hashimoto T, Nakashima J, Kashima T, et al. Clinical significance of preoperative renal function and gross hematuria for intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. Int J Urol 2017;24:111-6. [Crossref] [PubMed]
  18. Marchioni M, Primiceri G, Cindolo L, et al. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. BJU Int 2017;120:313-9. [Crossref] [PubMed]
  19. Ishioka J, Saito K, Kijima T, et al. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU Int 2015;115:705-12. [Crossref] [PubMed]
  20. Long X, Qi L, Zu X, et al. Prevention of Recurrent Bladder Tumors after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: An Individualized Selection Strategy Based on Patient Risk Stratification Is Needed. Urol Int 2017;98:312-9. [Crossref] [PubMed]
  21. Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol 2018;73:111-22. [Crossref] [PubMed]
  22. Yuan H, Mao X, Bai Y, et al. The effect of intravesical chemotherapy in the prevention of intravesical recurrence after nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis. J Chemother 2015;27:195-200. [Crossref] [PubMed]
  23. Long X, Zu X, Li Y, et al. Epidermal Growth Factor Receptor and Ki-67 as Predictive Biomarkers Identify Patients Who Will Be More Sensitive to Intravesical Instillations for the Prevention of Bladder Cancer Recurrence after Radical Nephroureterectomy. PLoS One 2016;11:e0166884. [Crossref] [PubMed]
  24. Tanaka N, Kikuchi E, Kanao K, et al. Independent predictors for bladder outcomes after treatment of intravesical recurrence following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma. Ann Surg Oncol 2014;21:3151-8. [Crossref] [PubMed]
  25. Elawdy MM, Osman Y, Taha DE, et al. Risk factors and prognosis of intravesical recurrence after surgical management of upper tract urothelial carcinoma: A 30-year single centre experience. Arab J Urol 2017;15:216-22. [Crossref] [PubMed]
Cite this article as: Sanguedolce F, Cormio L. The complex relationship between upper urinary tract and bladder cancer: clinical and predictive issues. Transl Androl Urol 2018;7(Suppl 2):S248-S251. doi: 10.21037/tau.2018.05.07